The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in ...

A new study from New York City-based Mount Sinai has found that commonly used wearable devices such as Apple watches, Fitbits and Oura rings may be able to identify, differentiate and predict ...

According to new research, wearables like an Apple Watch or an Oura smart ring can detect the symptoms and predict flare-ups ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Omvoh's approval as a treatment for Crohn's disease was based on results from a study in which 53% of patients treated with the drug achieved clinical remission, and 46% of patients had visible ...